VANCOUVER, Oct. 29, 2019 /CNW/ – Cognetivity Neurosciences Ltd. (the “Company” or “Cognetivity”) (CSE: CGN; FWB: 1UB; OTCQB: CGNSF) today confirmed that it has assessed sufficient participants in the clinical evaluation study of its Integrated Cognitive Assessment (ICA) platform to register for CE marking.
The news means Cognetivity remains on track to register the ICA as a medical device by the end of 2019, enabling the product to be launched in the United Kingdom and the EU.
“We’re extremely satisfied to have passed this critical milestone in the commercial development of our technology,” said Cognetivity’s CEO, Dr Sina Habibi. “And of course, every new test-taker represents an addition to our available data, which only serves to improve the quality of our Artificial Intelligence (AI) engine and thus the product itself.”
Cognetivity’s ICA platform, through the use of advanced AI techniques, has the potential to assist in the identification and monitoring of cognitively-impaired individuals with high accuracy and improved cost-effectiveness. The ICA can be seamlessly integrated into existing care pathways in clinical practice, leading to increased efficiency for clinicians and better outcomes for both patients and families.
The important progress Cognetivity has made comes at a particularly salient moment, as global pharmaceutical giants Biogen and Eisai recently announced that they intend to file for FDA approval of aducanumab in early 2020. This drug would be the first disease-modifying therapy for Alzheimer’s Disease to reach the market, injecting much-needed impetus into the field of drug development for neurodegenerative disease and potentially improving the lives of millions of patients.
Crucially, the prospect of such therapies highlights the need for validated tools that can help to identify patients when interventions are at their most effective. Given its immunity to practice effects and capacity for remote administration, the ICA is well positioned to make a major impact.
About Cognetivity Neurosciences Ltd.
Cognetivity is a technology company developing a cognitive testing platform, the Integrated Cognitive Assessment (ICA) for use in medical, commercial and consumer environments. Cognetivity’s ICA uses Artificial Intelligence and machine learning techniques to help detect the earliest signs of impairment by testing the performance of large areas of the brain, potentially allowing early diagnosis of dementia. Cognetivity aims to develop the ICA through ongoing clinical studies to the market in North America, Europe and elsewhere in the world.
For more information, please visit: www.cognetivity.com
ON BEHALF OF THE BOARD
Chief Executive Officer and Director
FORWARD LOOKING STATEMENTS:
The forward-looking information contained in this press release is made as of the date of this press release and, except as required by applicable law, the Company does not undertake any obligation to update publicly or to revise any of the included forward-looking information, whether as a result of new information, future events or otherwise, except as may be required by law. By its very nature, such forward-looking information requires the Company to make assumptions that may not materialize or that may not be accurate. This forward-looking information is subject to known and unknown risks and uncertainties and other factors, which may cause actual results, levels of activity and achievements to differ materially from those expressed or implied by such information.
The Exchange does not accept responsibility for the adequacy or accuracy of this release
SOURCE Cognetivity Neurosciences Ltd
For further information: Email: email@example.com, For media enquiries contact: Josh Stanbury, Email: firstname.lastname@example.org